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CliNiCal OutCOmes aNd Budget imPaCt Of COBas® egfr mutatiON test 
Versus saNger sequeNCiNg iN the treatmeNt Of lOCally adVaNCed Or 
metastatiC NsClC: a uNited states Payer PersPeCtiVe
Poulios N.1, Hertz D.2, Gavaghan M.2
1Roche Molecular Diagnostics, Pleasanton, CA, USA, 2GfK Market Access, Wayland, MA, USA
Objectives: Personalized medicine has become standard of care in directing 
treatment with tyrosine kinase inhibitors in locally advanced or metastatic NSCLC 
patients, but various testing methods for identifying EGFR mutations exist. We 
compared the clinical outcomes and budget impact of using the FDA-approved 
cobas® EGFR Mutation Test versus Sanger sequencing for identifying EGFR muta-
tions in locally advanced or metastatic NSCLC patients from a US payer per-
spective. MethOds: A decision-tree model was developed to compare testing 
methodologies and resulting treatment pathways in a hypothetical NSCLC US 
population health plan with 5 million covered lives and a baseline EGFR muta-
tion prevalence of 16.6%. Model inputs included parameters describing mutation 
testing accuracy treatment response (EGFR inhibitor, standard chemo therapy or 
best supportive care). Inputs were based on published literature and Medicare 
fee schedule reimbursement. Outcomes of the model included patients with test 
failures (based on detection limits of testing), average patient survival time and 
budget impact. Results: Patients whose samples were tested with the cobas® 
EGFR Mutation Test were less likely to experience test failures due to unusable tis-
sue samples compared to Sanger sequencing (6 test failures versus 57, respectively). 
Patients using the cobas® EGFR mutations testing received more appropriate care 
compared to Sanger sequencing (90% vs 82%, respectively), resulting in an average 
total survival increase of 0.6 months. Costs associated with diagnostic testing were 
$24,562 less than testing with Sanger sequencing, resulting in similar overall costs 
per member per month ($0.56). cOnclusiOns: Performing EGFR mutation testing 
with the cobas® EGFR Mutation Test has advantages from both patient outcomes 
and payer budget impact perspectives. By correctly identifying more patients for 
proper treatment with less test failures, the cobas® EGFR Mutation Test is a cost-
effective strategy for identification of EGFR mutations in locally advanced or meta-
static NSCLC patients from a US payer perspective.
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a CaNadiaN COst imPaCt aNalysis COmPariNg maiNteNaNCe theraPy 
with BOrtezOmiB Versus leNalidOmide iN multiPle myelOma PatieNts 
iNeligiBle fOr stem Cell traNsPlaNt
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Objectives: Approximately 7,000 Canadians have multiple myeloma (MM). Without 
effective treatment, patients can suffer from a constellation of disease-related 
symptoms that significantly reduce quality of life and survival. Management of stem 
cell transplant (SCT) ineligible MM patients is complex and varied. Maintenance 
therapies (MTs) after various induction regimens have been shown to improve 
response rate and progression-free survival. We sought to compare Canadian costs 
between two common approaches to MT, either bortezomib or lenalidomide, in 
MM patients ineligible for SCT. MethOds: The total annual drug cost of the two 
MT options were calculated and compared. Costs were based on 1.3mg/m2 of bort-
ezomib on days 1, 4, 8, 11 every three months, plus 50 mg of prednisone every 
other day, or 10 mg of lenalidomide on days 1 through 21 of each 28-day cycle. 
Administration costs including oncology nursing time and pharmacist workload, 
and pharmacy costs including a 10% markup and dispensing fees were added to the 
acquisition cost of bortezomib and lenalidomide, respectively. Unit and labour costs 
were obtained from public Canadian sources. Additional analyses were conducted 
to consider the impact of several variables including the management of adverse 
events, treatment duration and alternate costing assumptions. Results: The total 
annual costs of treatment per patient were $20,106, and $108,741 for bortezomib 
and lenalidomide, respectively. The incremental differences were robust to changes 
in inputs and assumptions (to be presented in poster). cOnclusiOns: The results 
of this analysis suggest that substantial savings were associated with bortezomib 
MT when compared with lenalidomide MT. As drug costs represent an increasing 
proportion of public spending in Canada, it is important to consider both efficacy 
and cost of treatment. Further studies are required to determine the complete cost-
benefit of available MTs.
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Objectives: In the UK, anastomotic leak rate after colorectal surgeries has been 
reported up to 19%. Yet, clinical and economic consequences of anastomotic leak 
have not been clearly articulated. Our study aims to estimate the clinical/economic 
burden of anastomotic leak following colorectal surgeries in the UK. MethOds: The 
Hospital Episode Statistics database was used to identify English National Health 
Service Trust adult patients undergoing colorectal surgeries between January 2007 
and December 2011. Anastomotic leak was identified by re-intervention/diagnosis 
codes within a 30-day window following colorectal surgery, including re-opera-
tion, re-anastomosis, stent, colostomy, image guided drainage, washout procedure, 
abscess/drainage and diagnosis of generalized (acute) peritonitis. Hospital costs 
were calculated using Healthcare Resource Group and Department of Health refer-
ence index costs. Differences in outcomes between groups were compared using a 
propensity score matching approach, adjusting for age, gender, admission method, 
surgery type, comorbidity and medical stabilization. Results: A total of 131,689 
patients received colorectal surgeries (mean age: 65.2±15.4, male: 50.4%). The rate 
Objectives: Based on evidence from the National Lung Cancer Screening Trial 
(NLST), the U.S. Preventive Services Task Force(USPSTF) recently recommended 
annual low-dose computed tomography(LDCT) screening for patients that are age 
55-80, have a 30 pack-year smoking history, and currently smoke or quit within the 
past 15 years. Under the terms of the Affordable Care Act, participating plans must 
cover this screening procedure. We project the 5-year clinical, resource, and budget 
impact of implementing this policy. MethOds: We developed a forecasting model 
to estimate the 5-year incremental outcomes of implementing LDCT screening in 
accordance with USPSTF recommendations versus no screening. We considered 
commercial (age < 65) and Medicare (age 65+) populations with 165.1 million and 
51.7 million enrollees, respectively (in accordance with national insurance esti-
mates). Age-specific lung cancer detection rates and stage at diagnosis was derived 
from the NLST. Included costs were LDCT screening and follow-up, confirmatory 
bronchoscopy/biopsy, and stage-specific treatment (initial,continuing,terminal 
care). We estimated lung cancers detected, LDCT scans, and the total and per-
member per-month(PMPM) budget impact of covering LDCT screening, assuming 
100% adherence to USPSTF recommendations in the base case. Monetary results 
are reported in 2013 USD and discounted at 3% per year. Results: In commercial 
and Medicare plans, LDCT screening is expected to result in 84,000 and 141,000 
more lung cancers detected (predominantly Stage I),22.4 million and 37.5 million 
more LDCT scans,and increased overall expenditure of $16.4 billion(PMPM= $1.65) 
and $27.4 billion(PMPM= $8.84), respectively. The most influential parameters were 
the proportion of “high risk” patients electing to undergo screening, the rate of 
screening adoption in the community, and the initial treatment cost of early-stage 
lung cancer. cOnclusiOns: Our analysis suggests that coverage of LDCT lung 
cancer screening is expected to increase lung cancer diagnoses,result in a greater 
proportion of early-stage disease diagnoses, and substantially increase health plan 
expenditure, particularly in Medicare.
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COst aNalysis Of adVerse eVeNts assOCiated with first liNe 
treatmeNt fOr metastatiC reNal Cell CarCiNOma (mrCC) iN the 
PersPeCtiVe Of PuBliC aNd PriVate health iNsuraNCe iN Brazil
Ferreira C.N., Rufino C.S., Manfrin D.F.
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Objectives: This study analyzes the cost of adverse events associated with 
metastatic renal cell carcinoma (mRCC) treatments of pazopanib and suni-
tinib. MethOds: A cost analysis was performed based on the published data of 
the COMPARZ study. All adverse events (AEs) were identified based on the AEs 
reported in this study, Cost information related to the the treatment of the most 
frequent adverse events (> 15%) in the study population (n= 1,100 individuals) 
were obtained. These events included in the analysis were hepatotoxicity, anemia, 
nausea, fatigue and diarrhea. The perspective adopted in this analysis was of the 
Unified Health System (SUS) and Brazilian Supplementary Healthcare (SS). For reck-
oning purposes, the Medication Market Regulation Chamber (CMED/ ANVISA) listed 
prices were used. Results: From the perspective of the SUS, the following results 
are reported: nausea (sunitinib = BRL157.30 vs pazopanib = BRL176.49); anemia 
(sunitinib = BRL33.40 vs pazopanib = BRL14.32); fatigue (sunitinib = BRL18.00 vs 
pazopanib = BRL9.36); diarrhea (sunitinib = BRL73.09 vs pazopanib = BRL125.87) and 
hepatotoxicity (sunitinib = BRL416.18 vs pazopanib = BRL407.13). When consider-
ing costs incurred from private pay perspective such as SS, we observed the values 
were: nausea (sunitinib = BRL697.00 vs pazopanib = BRL782.00); anemia (sunitinib 
= BRL188.52 vs pazopanib = BRL80.79); fatigue (sunitinib = BRL163.11 vs pazopanib 
= BRL84.81) diarrhea (sunitinib = BRL248.66 vs pazopanib = BRL428.24) and hepa-
totoxicity (sunitinib = BRL2,080.90 vs pazopanib = BRL2,035.67). Thus, as from total 
estimated AE events cost, the SUS disbursed approximately BRL697.97 when the first 
line therapeutic option was sunitinib and BRL733.16 with pazopanib. In SS, it was 
paid around BRL3,378.18 and BRL3,411.51, respectively. cOnclusiOns: A therapy 
that has less financial impact on the treatment of adverse events is the choice of 
sunitinib for both public (5% decrease) and private (1%) targets.
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Objectives: A substantial proportion of prostate cancer care (PCa) is expected 
to be completed in the outpatient hospital setting, particularly as more hospitals 
systems acquire oncology practices. However, there is very limited information on 
practice-specific costs of care for patients receiving chemotherapeutic treatments 
within this unique setting. This study evaluated the cost of care for chemotherapy 
treatment in the outpatient hospital setting for PCa patients with bone metasta-
ses. MethOds: Patients in the Premier Hospital Database between January 2006 
and December 2010 treated in an outpatient setting for PCa (ICD-9-CM Codes 185 
and 233.4) were selected. Patients were required to be ≥ 40 years of age and have no 
additional cancers and evidence of bone metastases (ICD-9-CM code 198.5 or the 
use of zoledronic acid or pamidronate disodium). Costs of care per visit across cost 
centers were evaluated and described. Results: There were 5,223 outpatient visits 
for men treated for PCa with bone metastases. The mean age of the sample was 71 
years, with 64% being Caucasian. The average visit cost was $4,614. Pharmacy costs 
($4,119) represent 89.2% of total visit costs, followed by professional ($190) and labo-
ratory expenses ($77). Chemotherapy costs represented 47% of total pharmacy costs, 
with the most commonly specified chemotherapies being docetaxel, mitoxantrone, 
and carboplatin. cOnclusiOns: Men treated for PCa with bone metastases treated 
in an outpatient setting averaged $4,614 per visit, with pharmaceutical costs rep-
resenting almost 90% of care.
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with prevention of chronic disease and cancer over a one-year time horizon in the 
US. Age- and sex-specific population statistics, incidence, and mortality rates were 
used to model the prevalence and costs of chronic disease (Alzheimer’s, depres-
sion/suicide, diabetes, heart failure, Parkinson’s, stroke) and cancer (bladder, breast, 
colorectal, endometrial, esophageal, leukemia, liver, oral, pancreatic, prostate). 
Relative risks of chronic diseases and cancers by cups of coffee consumed daily 
were obtained from meta-analyses of prospective cohort and case-control studies. 
US daily coffee consumption, duration of disease, and attributable disease costs 
were obtained from the literature. The model was validated by comparing predicted 
disease-specific health care costs to estimates from published disease burden analy-
ses. Probabilistic sensitivity analysis (PSA) was conducted. Results: The model 
estimates that US coffee consumption prevents over 50,000 chronic disease and 
cancer deaths per year and results in an estimated health care savings of $33.4 bil-
lion per year (95% CI: $28.7bn, $38.3bn) of which $30.0bn is due to chronic disease 
and $3.4bn due to cancer. Cost savings were greatest for diabetes ($23.0bn), stroke 
($2.7bn), depression ($1.6bn), heart failure ($1.4bn), and Alzheimer’s disease ($1.1bn). 
In the PSA breast cancer and colorectal cancer were the only disease states in which 
the 95% CI ranged over no cost savings. cOnclusiOns: This analysis suggests a 
potential public health benefit and health economic savings associated with cof-
fee consumption. Given the limitations of effectiveness data obtained from obser-
vational studies, additional research on the health effects of coffee is warranted.
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exCess health Care COsts amONg elderly Breast CaNCer PatieNts, 
By reCeiPt Of humaN ePidermal grOwth faCtOr reCePtOr 2-targeted 
theraPy: aN aNalysis Of seer-mediCare data
Hao Y.1, Lang K.2, Huang H.2, Lin I.2, Rogerio J.W.1, Menzin J.2
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Objectives: Few studies have examined excess health care costs among elderly 
breast cancer (BC) patients by receipt of human epidermal growth factor receptor 
2- (HER2-) targeted therapy. MethOds: Women aged 65+ with an incident diagnosis 
of BC (index) and no history of other cancer were identified from 2006-2010 linked 
Surveillance, Epidemiology, and End Results (SEER) and Medicare data. Women were 
divided into two cohorts based on receipt of HER2-targeted therapy (trastuzumab 
or lapatinib) and matched 1:1 to non-cancer comparison cohorts by age, sex, and 
race. Continuous enrollment from 1 year pre-index (baseline) through disenroll-
ment, death, or the end of the data was required. All-cause costs were evaluated 
per-patient-per-month (PPPM) overall and by stage. Generalized linear models 
were constructed to identify factors associated with costs, by stage, controlling for 
demographics and comorbidity. Results: We identified 1,746 BC patients receiv-
ing and 35,114 not receiving HER2-targeted therapy. Unadjusted excess total costs 
(vs. non-cancer patients) were $4,079 PPPM for the HER2-targeted cohort and $990 
for the no HER2-targeted cohort (both P < 0.001), with larger differences at more 
advanced stages. Excess cost drivers were outpatient care and physician/provider 
services (including HER2-targeted therapy acquisition and administration costs). 
In multivariate analyses, Stage I HER2-targeted BC patients experienced 3.17 times 
greater total costs than non-cancer patients; while those with Stages II, III, and IV 
had 3.02, 3.40, and 4.27 times greater costs respectively (all P < 0.001). Similar trends 
with generally smaller magnitudes were observed among patients without HER2-
targeted therapy (0.48 [I]; 0.83 [II]; 1.67 [III]; 4.33 [IV]; all P < 0.001). Other significant 
cost predictors included older age, Black or Hispanic race, and baseline Charlson 
score> 2. cOnclusiOns: Women with BC experience higher costs than non-cancer 
patients, with greater burden among those receiving HER2-targeted therapy. Excess 
cost drivers were outpatient care and physician/provider services.
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Objectives: To compare costs associated with health care resource use in patients 
with advanced renal cell carcinoma (RCC) receiving first-line treatment with pazo-
panib versus sunitinib. MethOds: COMPARZ was a multi-country, randomized, 
open-label, phase III study which demonstrated non-inferiority of pazopanib 
compared to sunitinib in adult patients with advanced RCC and no prior systemic 
therapy. Treatment continued until disease progression, unacceptable toxicity, with-
drawal of consent, or death. We estimated total costs by combining non-protocol 
health care resource use with standardized price weights from a US claims data-
base, and tracked from treatment initiation to study endpoint. Unadjusted and 
adjusted cost data were compared using univariate parametric (t-test) and non-
parametric (Kaplan Meier Sample Average [KMSA]) tests to account for skewness 
and right-censoring. We estimated 80% power to detect a difference of $8,000 in 
total costs (two-sided test), assuming α = 0.05. Additional analyses were performed 
to account for non-normal distribution of the data. Results: A total of 906 out of 
1,110 enrolled subjects (N= 454 pazopanib and N= 452 sunitinib) reported resource 
use data. Mean follow-up was 10.6 months. Both arms were balanced at baseline 
for clinical and demographic characteristics. The population was 73% male, mean 
age of 61 and good performance status (76% had Karnofsky score 90-100). Rates of 
emergency visits/hospital days, provider contacts, diagnostics, and procedures were 
greater for patients receiving sunitinib compared to pazopanib. Mean costs were 
$12,120 for pazopanib-treated patients and $15,727 for sunitinib-treated patients 
(p= 0.02), a difference of 29.7%. KMSA-derived costs were $21,026 for pazopanib and 
$29,043 for sunitinib. Cost differences between arms were significant when using 
Ordinary Least Squares and Generalized Linear Model approaches to adjust for 
of anastomotic leak following colorectal surgery was 6.4% (8,404 out of 131,689). 
After propensity score matching by key covariates, Patients with leak (vs. without 
leak) had higher in-hospital mortality (15.9% (95% CI: 15.2%, 16.7%) vs. 6.2% (95% CI: 
5.7%, 6.7%), p< 0.001), 30-day readmission rate (19.7% vs. 11.6%, p< 0.001), and post-
operative infection rate (19.3% vs. 4.5%, p< 0.001). The hospitalizations for patients 
with leak (vs. without leak) were more costly (£9,071±£4,588 vs. £6,420±£2,895, 
p< 0.001) and longer (20±23 vs. 11±13 days, p< 0.001). Anastomotic leak resulted in 
an additional cost of £2651 and an extra LOS of 9 days per patient. cOnclusiOns: 
Our findings underscore the clinical/economic burden of anastomotic leak after 
colorectal surgeries in the UK. The presence of anastomotic leak was associated with 
greater mortality, LOS, and costs, highlighting the importance of providing prompt 
medical attention to minimize the impact of anastomotic leak.
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Objectives: The aim of the analysis was understand the cost differences 
between the treatment with subcutaneous (SC) and intravenous (IV) bortezomib 
in patients with Multiple Myeloma treated by the Brazilian Private HealthCare 
System. MethOds: A treatment cost model was developed to estimate and com-
pare the total costs for the treatments with SC and IV. The main inputs used in 
the model were: medication cost, adverse events cost, average number of cycles, 
infusion costs and total time of infusion. The model analyzed total costs from the 
perspective of payers (HMOs) and service provider (Infusion Clinic). Pharmaceutical 
unit costs were obtained from official government price list applying reimbursement 
inflators. Infusion time, dose, and number of cycles were obtained from published 
literature. Deterministic sensitivity analysis (DSA) was performed to assess robust-
ness of the model results. Results: The total infusion time per patient was 37.8 
minutes for SC and 75.4 minutes for IV. The medication factory price (MFP) was the 
same for both treatments with a reimbursement inflator of 15% in MFP. The Total 
Costs considering the HMO perspective were R$80,536.04 for SC and R$81,009.78 
for IV per patient. The comparison between the treatments generates a difference 
of -R$473.74. From the Infusion Clinic perspective the Total Costs were R$67,129.44 
for SC and R$67,881.02 for IV per patient. The total reimbursement (difference from 
income and cost) generated for the service provider was R$12,558.30 for IV and 
R$12,882.21 for SC per patient. The reimbursement comparison presented a financial 
return of R$323.91 per patient. In DSA, the SC formulation remained as the option 
associated with a lower economical impact for the HMO and a better financial return 
for the infusion clinic in all scenarios. cOnclusiOns: The SC treatment compared 
with the IV treatment may generate saving for HMO and a rise of reimbursement 
for service provider.
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Objectives: Multiple myeloma (MM) is the second most prevalent blood cancer in 
Canada. In patients who have undergone autologous stem cell transplant (ASCT); 
post-transplant maintenance therapy (MT) has been associated with substantial 
prolongation of progression-free survival. Consensus guidelines support the use of 
lenalidomide and bortezomib as post-transplant MTs, though these agents are sup-
ported by differing levels of clinical evidence. We sought to quantify and compare 
potential cost differences between two MTs, bortezomib and lenalidomide, in MM 
patients who have undergone ASCT. MethOds: The total annual drug cost of the 
two MT options were calculated. Costs were based on 1.3 mg/m2 of bortezomib every 
two weeks, or 10 mg of lenalidomide daily. The cost of administration including 
oncology nursing time and pharmacist workload was added to the acquisition cost 
of bortezomib. Pharmacy costs including a 10% markup and dispensing fees were 
added to the acquisition cost of lenalidomide. Unit and labour costs were obtained 
from public Canadian sources. Additional analyses were conducted to consider the 
impact of several variables including the management of adverse events, treatment 
duration and alternate costing assumptions. Results: The total annual costs of 
treatment per patient were $32,560 and $144,976 for bortezomib and lenalidomide, 
respectively. The incremental differences were robust to changes in inputs and 
assumptions (to be presented in poster). cOnclusiOns: In the absence of clear 
comparative clinical efficacy, the choice of MT may be influenced by patient char-
acteristics as well as patient and physician preference. Taken together, the results 
of this analysis suggest that when comparing MTs, bortezomib is much less costly 
than lenalidomide and therefore there are important cost differences that should 
also be considered.
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Of ChrONiC disease aNd CaNCer iN the uNited states
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Objectives: Over half of US adults consume coffee (Coffea arabica) on a daily basis. 
Epidemiologic studies suggest coffee may prevent some chronic diseases and can-
cers. This analysis aims to quantify the potential health economic impact of coffee 
consumption in the US. MethOds: A period life-table analysis was developed to 
estimate the total direct health care cost savings of coffee consumption associated 
